KR20210149141A - 삼중특이적 결합 단백질, 이의 방법 및 용도 - Google Patents

삼중특이적 결합 단백질, 이의 방법 및 용도 Download PDF

Info

Publication number
KR20210149141A
KR20210149141A KR1020217036094A KR20217036094A KR20210149141A KR 20210149141 A KR20210149141 A KR 20210149141A KR 1020217036094 A KR1020217036094 A KR 1020217036094A KR 20217036094 A KR20217036094 A KR 20217036094A KR 20210149141 A KR20210149141 A KR 20210149141A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
sequence
cdr
Prior art date
Application number
KR1020217036094A
Other languages
English (en)
Korean (ko)
Inventor
즈-용 양
요르크 비르켄펠트
개리 제이. 네이블
화웨이 치우
요르크 레굴라
에드워드 세웅
로니 웨이
란 우
전 싱
링 쉬
카트린 프라드
타릭 다브도우비
베아트리체 카메론
썽드린 르무완
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20210149141A publication Critical patent/KR20210149141A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217036094A 2019-04-09 2020-04-08 삼중특이적 결합 단백질, 이의 방법 및 용도 KR20210149141A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
US62/831,572 2019-04-09
EP19306261.9 2019-10-02
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
KR20210149141A true KR20210149141A (ko) 2021-12-08

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217036094A KR20210149141A (ko) 2019-04-09 2020-04-08 삼중특이적 결합 단백질, 이의 방법 및 용도

Country Status (13)

Country Link
EP (1) EP3953388A1 (ja)
JP (1) JP2022527994A (ja)
KR (1) KR20210149141A (ja)
CN (1) CN113950484A (ja)
AU (1) AU2020272839A1 (ja)
BR (1) BR112021019915A2 (ja)
CA (1) CA3136821A1 (ja)
CO (1) CO2021014918A2 (ja)
IL (1) IL286929A (ja)
MX (1) MX2021012386A (ja)
SG (1) SG11202111012QA (ja)
TW (1) TW202104261A (ja)
WO (1) WO2020210392A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077118A2 (en) * 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) * 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2016033690A1 (en) * 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
PE20171764A1 (es) * 2015-01-23 2017-12-21 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
WO2016205531A2 (en) * 2015-06-17 2016-12-22 Genentech, Inc. Anti-her2 antibodies and methods of use
BR112018008011A2 (pt) 2015-10-25 2018-10-30 Sanofi proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
CN117964758A (zh) * 2017-10-10 2024-05-03 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
US11530268B2 (en) * 2018-10-09 2022-12-20 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

Also Published As

Publication number Publication date
JP2022527994A (ja) 2022-06-07
SG11202111012QA (en) 2021-11-29
CO2021014918A2 (es) 2021-11-19
AU2020272839A1 (en) 2021-12-02
TW202104261A (zh) 2021-02-01
CA3136821A1 (en) 2020-10-15
CN113950484A (zh) 2022-01-18
MX2021012386A (es) 2022-01-18
EP3953388A1 (en) 2022-02-16
BR112021019915A2 (pt) 2021-12-07
WO2020210392A1 (en) 2020-10-15
IL286929A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CN109476732B (zh) 三特异性和/或三价结合蛋白
JP7387780B2 (ja) 抗ｃｄ３８抗体および使用方法
JP7462621B2 (ja) 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
US11613576B2 (en) Trispecific binding proteins, methods, and uses thereof
IL301140A (en) Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection
US11932704B2 (en) Trispecific and/or trivalent binding proteins
US20220089767A1 (en) Cd47-cd38 bispecific antibodies
KR20210149141A (ko) 삼중특이적 결합 단백질, 이의 방법 및 용도
RU2812910C2 (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28